New Documents on National Centralized Drug Procurement Released

Recently, the Office for the Centralized Procurement of Drugs Organized by the State has released the National Centralized Drug Procurement Document (GY-YD2025-1) (the "Procurement Document").

According to the Procurement Document, under this round of centralized procurement, each region, and even each medical institution, may have multiple winning enterprises supplying drugs. The execution of procurement results will be further strengthened. Winning enterprises are required to assume primary responsibility for supply assurance, promptly respond to orders from medical institutions, and complete distribution. Medical institutions are required to give priority to purchasing winning products, fulfill the agreed procurement volume on schedule under the agreement, and make timely payments. The Procurement Document stipulates that, during the procurement cycle, if a winning enterprise, without justifiable reason, fails to fulfill its supply commitments, thereby affecting clinical use, it will be placed on a "list of Violators" depending on the circumstances, disqualified from winning status, and barred from participating in future national centralized drug procurement activities for a period ranging from six months to five years. The Procurement Document also makes clear that this round of procurement pays particular attention to ensuring the supply of medicines for children.



(Source: https://www.nhsa.gov.cn/art/2025/9/20/art_109_17970.html)

Note: The link to the Chinese official website of the document is for your reference.